VUT-MK142 is a novel, potent and cardiomyogenic agent promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes, which may be useful to differentiate stem cells into cardiomyocytes for cardiac repair.
Physicochemical Properties
| Molecular Formula | C17H22N4O |
| Molecular Weight | 298.382783412933 |
| Exact Mass | 298.179 |
| CAS # | 1313491-22-3 |
| PubChem CID | 53261094 |
| Appearance | White to off-white solid powder |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 499.9±40.0 °C at 760 mmHg |
| Flash Point | 256.1±27.3 °C |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.638 |
| LogP | 5.35 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 22 |
| Complexity | 314 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O(C)C1C=CC(=CC=1)NC1=CC(=NC=N1)NC1CCCCC1 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | The cardiomyogenic effects of VUT-MK142 on various cell types are promising. It was observed that VUT-MK142 significantly affected P19 and C2C12 cells. Treatment with VUT-MK142 led to a stronger upregulation of ANF expression than CgC [1]. After 7 days of treatment, VUT-MK142 (1 μM) significantly (p < 0.05) increased the luciferase signal in P19 cells by 3.1 ± 0.3 luciferase (n = 5) times [1]. |
| References | [1]. Moumita Koley, et al. VUT-MK142 : a new cardiomyogenic small molecule promoting the differentiation of pre-cardiac mesoderm into cardiomyocytes. Medchemcomm. 2013 Aug 1;4(8):1189-1195. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~25 mg/mL (~83.79 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.38 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3514 mL | 16.7572 mL | 33.5143 mL | |
| 5 mM | 0.6703 mL | 3.3514 mL | 6.7029 mL | |
| 10 mM | 0.3351 mL | 1.6757 mL | 3.3514 mL |